Hugo Fry

Hugo Fry has an extensive career in the healthcare and biopharmaceutical industries. Hugo began their career in 2005 as a Business Unit Director, Marketing Director, and Marketing Support Director for sanofi-aventis in Russia. In 2010, they were appointed General Manager of Zentiva, where they were a member of the Global Zentiva Leadership team and responsible for a staff of over 500. In 2011, Fry was selected as the Global Project Leader for the Lixisenatide family of products at sanofi. In 2015, they were appointed Vice President and Chief Marketing Officer for Sanofi Pasteur MSD, where they were responsible for leading commercial strategy and execution for vaccines in Europe. In 2016, Fry joined The Association of the British Pharmaceutical Industry (ABPI) as Vice President and Board Member, representing innovative research-based biopharmaceutical companies. In 2021, Fry became Chief Commercial Officer at Imbria Pharmaceuticals and Chair of The Board at Zen Intelligence. Hugo is currently Chief Executive Officer at RQ Biotechnology Ltd.

Hugo Fry attended The University of Salford from 1990 to 1993, where they earned a BSc in Chemistry. In 2010, they attended London Business School to study Finance. In 2014, they attended Duke University to study Leadership.